Kimia Biosciences Limited is an Indian pharmaceutical company specializing in the research, development, and large-scale manufacturing of **Active Pharmaceutical Ingredients (APIs)** and advanced intermediates. The company is currently undergoing a strategic transition from a domestic bulk drug supplier to an integrated global player, leveraging its **DSIR-recognized** research capabilities and expanding into the **Contract Development and Manufacturing Organization (CDMO)** sector. --- ### **Core Manufacturing Infrastructure & Operational Footprint** The company operates through a centralized manufacturing hub supported by strategic external partnerships to maintain a diverse product catalog. * **Primary Manufacturing Facility:** Located at **Village Bhondsi, Tehsil Sohna, Gurgaon (Haryana)**. The plant is certified by the **State FDA, Haryana**, and has been revamped to meet **Good Manufacturing Practice (GMP)** standards. * **Infrastructure Upgrades:** The company is currently executing a multi-year **CAPEX** plan, investing **₹10-12 Crores in FY 2023-24** and an additional **₹15-20 Crores in FY 2024-25**. Key projects include: * Installation of a **3 TPH Capacity** boiler and new reactors (**₹2 Crore budget**) to enhance safety and operational life. * Construction of **Clean Rooms (Powder Processing Units)**. * Expansion of the **Effluent Treatment Plant (ETP)** with a **₹23 Lakh** investment to ensure environmental compliance. * **External Production:** To optimize capacity, the company utilizes **job-work arrangements** with facilities in **Derabassi, Punjab**, and other domestic locations. * **Corporate Presence:** Recently inaugurated a corporate office in **Mumbai** to drive business development and global outreach. --- ### **Research, Development & Intellectual Property** Kimia’s growth is anchored by its **Department of Scientific and Industrial Research (DSIR)** recognized R&D center, which focuses on complex chemistry and import substitution. * **R&D Talent:** Employs over **60 scientists** across facilities in **Gurgaon** and a newly established center in **Hyderabad**. * **Product Pipeline:** * **Commercialized:** Over **25 products**, including **Fimasartan Potassium Trihydrate** (South Korea DMF approval) and **Bempedoic Acid** (India manufacturing permission). * **Under Development:** **9-10 molecules** targeting high-growth therapeutic areas, including **Apixaban, Empagliflozin, Sacubitril Valsartan, Vildagliptin, and Rifaximin (Alfa Form)**. * **Intellectual Property Portfolio:** * **Patents:** **9 patents** filed; granted a **20-year patent (No. 579384)** in **February 2026** for an improved process for **Luliconazole**. * **Trademarks:** Holds **Class 5 Trademark Registration** for pharmaceuticals and dietary supplements. * **Strategic Objective:** Focus on indigenous development of **Key Starting Materials (KSMs)** to reduce dependency on imports and improve margins. --- ### **Financial Performance & Capital Structure** The company achieved a significant financial turnaround in **FY 2024-25**, moving from consecutive years of losses to profitability. **Three-Year Financial Summary** | Metric (₹ in Lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **11,892.00** | **10,652.00** | **12,852.00** | | **Net Profit / (Loss)** | **961.00** | **(718.37)** | **(530.87)** | | **Net Worth** | **-** | **33.10** | **546.28** | | **Paid-up Equity Capital** | **473.13** | **473.13** | **473.13** | **Capital Management & Debt:** * **Promoter Holding:** Managing Director **Mr. Sameer Goel** holds a **74.94%** stake as of August 2024. * **Borrowing Profile:** Total current borrowings stand at **₹2,219.62 Lakhs**, primarily through **HDFC Bank** (Cash Credit and Term Loans at **9.22%–9.25%** interest). * **Preference Share Redemption:** Initiated the redemption of **0.1% Non-Convertible Cumulative Redeemable Preference Shares** in tranches starting **May 2025**, funded via distributable profits. * **Authorized Capital:** Total of **₹16.38 Crore**, including equity and convertible/non-convertible preference shares. --- ### **Strategic Growth & Market Expansion** Kimia is pivoting toward high-margin segments and international regulatory markets to diversify its revenue streams. * **CDMO Entry:** Secured a breakthrough contract from a **European client** valued at **USD 200,000** in late 2024, marking its entry into the high-value contract manufacturing space. * **Export Growth:** Reported a **30% exponential increase** in export earnings in **FY 2023-24**. The company has received **Written Confirmation** from the Indian Ministry of Health for **nine products** exported to the **European Union**. * **Global Compliance:** Upgrading facilities to meet **WHO certifications** and filing **Drug Master Files (DMFs)** in regulated markets like South Korea and the EU. * **Digital Transformation:** Increasing **IT investments** and implementing the **Vision 360 Tool** for real-time statutory compliance monitoring. --- ### **Risk Management & Governance Framework** The company operates an enterprise-wide risk management framework to address the inherent volatility of the pharmaceutical sector. **Key Risk Factors & Mitigation** * **Regulatory Compliance:** Following a **₹1.05 Crore penalty** from the **Haryana State Pollution Control Board** in FY23, the company engaged a **US-based consulting firm** to implement a **Quality Culture Excellence** program. * **Concentration Risk:** A single customer accounts for more than **10% of total revenue**, prompting a strategic push for client diversification through the new Mumbai office. * **Market Volatility:** Exposure to **spot price fluctuations** in raw chemicals is managed through senior-level procurement oversight and identifying alternative supply sources. * **Governance & Reporting:** * The company received a **warning letter** in **August 2025** for disclosure delays regarding its Annual Report. * Statutory auditors (**Sunil Suresh & Associates**) resigned in **April 2025** due to "commercial considerations" (time-cost recovery). * **Inventory Valuation:** Auditors noted **significant estimation uncertainty** regarding the **₹3,458.31 Lakhs** inventory valuation as of March 2025. --- ### **Leadership & Sustainability** Kimia is strengthening its board to support its technical and ESG (Environmental, Social, and Governance) goals. * **Executive Leadership:** **Mr. Sameer Goel** re-appointed as **MD** until **2031**. Technical leadership bolstered by **Mr. Prasad Raju** (Technical Director, June 2025) and **Mr. Kaku Vijaya Shekhar Reddy** (Executive Director, Dec 2025). * **ESG Commitment:** A decade-long sustainability framework is in place, focusing on **carbon emission reduction**, **renewable energy adoption**, and **biodiversity conservation**. * **Quality Assurance:** Implementation of quarterly compliance audits by transaction auditors to ensure adherence to global standards.